Oral News and Research

RSS

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Shionogi today announced that once-daily naldemedine met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

3 Aug 2015

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

15th Annual Geriatric Health Care Symposium now open for registration

Registration is now open for the 15th Annual Geriatric Health Care Symposium, "Maximizing Independence for Optimal Aging," presented by the University of Louisville Institute for Sustainable Health & Optimal Aging.

3 Aug 2015

Simple lifestyle intervention can help prevent gestational diabetes in high-risk women

Gestational diabetes can be prevented by a simple, easily applicable individualized lifestyle intervention in high-risk women, finds a study led by Helsinki University Hospital and South Karelia Central Hospital, Finland. The results of the study are promising, and in line with previous published T2D prevention studies. The findings may have major health consequences for both the mother and the child.

31 Jul 2015

Daiichi Sankyo, Plexxikon’s Phase 1 trial shows PLX3397 induced prolonged tumor regression in TGCT patients

Daiichi Sankyo Europe and Plexxikon Inc., a member of the Daiichi Sankyo Group, announced today that The New England Journal of Medicine published clinical trial results demonstrating that the investigational drug, PLX3397, an oral targeted CSF-1R inhibitor, induced prolonged tumor regressions in most patients with tenosynovial giant cell tumor, a rare, locally aggressive neoplasm of the joint or tendon sheath.

31 Jul 2015

Patients with HPV traces post-treatment more likely to have oropharyngeal cancer recurrence

Oropharyngeal cancer patients who were found to have detectable traces of human papillomavirus type 16 (HPV16) in their saliva following cancer treatment are at an increased risk for recurrence, a study led by researchers at the Johns Hopkins Bloomberg School of Public Health has found.

31 Jul 2015

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.

30 Jul 2015

New computer-based system provides real-time feedback before and during facial transplant surgery

Following several years of research and collaboration, physicians and engineers at Johns Hopkins and Walter Reed National Military Medical Center say they have developed a computer platform that provides rapid, real-time feedback before and during facial transplant surgery, which may someday improve face-jaw-teeth alignment between donor and recipient.

30 Jul 2015

UT Southwestern's Pulmonary Hypertension Program continues to grow in the U.S.

When Derrik Neal began having trouble breathing, he initially assumed it was because he was overweight. But after blacking out several times, he learned he had idiopathic pulmonary hypertension. Survival rates at the time he was diagnosed were five years or less - three or less if undetected.

30 Jul 2015

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL.

29 Jul 2015

New polymer gel could help create swallowable devices for ultra-long drug delivery

Medical devices designed to reside in the stomach have a variety of applications, including prolonged drug delivery, electronic monitoring, and weight-loss intervention. However, these devices, often created with nondegradable elastic polymers, bear an inherent risk of intestinal obstruction as a result of accidental fracture or migration. As such, they are usually designed to remain in the stomach for a limited time.

29 Jul 2015

Researchers establish safety, dosing of new drug for treating blood cancers

Researchers at University of California, San Diego School of Medicine have established the safety and dosing of a new drug for treating blood cancers. The findings are published online July 27 in The Lancet Haematology.

29 Jul 2015

TWi releases generic version of MEGACE ES (megestrol acetate oral suspension) 625mg/5ml

TWi Pharmaceuticals, Inc. today announced that it launched its generic version of Par Pharmaceutical's MEGACE ES (megestrol acetate oral suspension) 625mg/5ml after the United States District Court for the District of Maryland reinstated its finding that United States Patent No. 7,101,576 (the '576 Patent) is invalid.

29 Jul 2015

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.

28 Jul 2015

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

Researchers use silk fibers to grow stem cells into salivary gland cells

The silkworm, which produces the essential ingredient for fine silk fabric, also plays a critical role in a new process designed to provide relief for millions of individuals with dry mouth, a devastating oral and systemic health issue.

28 Jul 2015

Nutrition vital for patients recovering from severe burns

For someone recovering from severe burns, eating is often the last thing they want to do. However, burn specialists at The Ohio State University Wexner Medical Center say nutrition is so vital to their patients' recovery that they make it a quality indicator for patient care.

24 Jul 2015

New review article analyzes pros and cons of different treatment approaches to gallbladder disease

More than 25 million Americans have gallstones, and each year about 1 million new cases are diagnosed. Each year about 1.8 million people develop abdominal pain as a result of gallstones and go see a doctor about it. About 40 percent of these, more than 725,000 people a year, ultimately have surgery to resolve the problem.

23 Jul 2015

More people turn to popular new blood thinners for atrial fibrillation treatment

More adults than ever are visiting their doctors' offices for a prescription to treat atrial fibrillation, according to a study led by the University of Michigan Frankel Cardiovascular Center.

23 Jul 2015

Oral News and Research

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Array Biopharma reports strong fourth quarter and full year 2015 financial results

15th Annual Geriatric Health Care Symposium now open for registration

Simple lifestyle intervention can help prevent gestational diabetes in high-risk women

Daiichi Sankyo, Plexxikon’s Phase 1 trial shows PLX3397 induced prolonged tumor regression in TGCT patients

Patients with HPV traces post-treatment more likely to have oropharyngeal cancer recurrence

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

New computer-based system provides real-time feedback before and during facial transplant surgery

UT Southwestern's Pulmonary Hypertension Program continues to grow in the U.S.

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

New polymer gel could help create swallowable devices for ultra-long drug delivery

Researchers establish safety, dosing of new drug for treating blood cancers

TWi releases generic version of MEGACE ES (megestrol acetate oral suspension) 625mg/5ml

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

Researchers use silk fibers to grow stem cells into salivary gland cells

Nutrition vital for patients recovering from severe burns

New review article analyzes pros and cons of different treatment approaches to gallbladder disease

More people turn to popular new blood thinners for atrial fibrillation treatment

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News